Section Arrow
CGON.NASDAQ
- CG Oncology
Quotes are at least 15-min delayed:2026/05/23 00:43 EDT
Regular Hours
Last
 64.25
-0.34 (-0.53%)
Day High 
65.395 
Prev. Close
64.59 
1-M High
75.5 
Volume 
652.82K 
Bid
63.5
Ask
65
Day Low
63.57 
Open
64.48 
1-M Low
61.02 
Market Cap 
5.70B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 67.71 
20-SMA 67.4 
50-SMA 67.28 
52-W High 75.5 
52-W Low 23.65 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.34/-2.75
Enterprise Value
5.70B
Balance Sheet
Book Value Per Share
12.38
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
191.00K
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
GOVXGeoVax Labs Inc.3.64+0.89+32.36%-- 
MTVAMetaVia Inc.3.85+0.98+34.15%-- 
AKTXAkari Therapeutics Plc18.27+13.13+255.45%-- 
LIMNLiminatus Pharma Inc0.1694-0.0766-31.14%-- 
IOVAIovance Biotherapeutics4.11+0.41+11.08%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.